Renal safety can be managed with appropriate dosing strategies

For patients whose renal function is impaired, the dose of ZOMETA^® can be adjusted to prevent safety issues¹
- — During treatment, serum creatinine should be measured before each ZOMETA dose
- — Monitor renal function and withhold therapy temporarily if patients demonstrate renal
  deterioration^*
- — Resume therapy at the dose that was used prior to treatment interruption when serum creatinine returns to within 10% of baseline value

Starting Dose of zometa by baseline creatinine clearance

Use the creatinine clearance calculator to determine your patient's baseline creatinine clearance

*Renal deterioration is defined as an increase of 0.5 mg/dL or 44 μmol/L in patients with normal baseline serum creatinine (<1.4 mg/dL or <124 μmol/L), or as an increase of 1.0 mg/dL or 88 μmol/L in patients with abnormal baseline serum creatinine (>1.4 mg/dL or >124 μmol/L).
^†Doses calculated assuming target AUC of 0.66 (mg•hr/L) (creatinine clearance=75 mL/min).